Penn Epidemiological Study Shows Difference In Cardiovascular Effects Between Vioxx And Celebrex

In the first epidemiological study designed and executed specifically to determine the heart-attack risk associated with COX-2 inhibitors rofecoxib (Vioxx) and celecoxib (Celebrex), researchers at the University of Pennsylvania School of Medicine found a greater risk of heart attack associated with Vioxx than Celebrex, although neither of ...

Continue to Penn Epidemiological Study Shows Difference In Cardiovascular Effects Between Vioxx And Celebrex on ScienceDaily Headlines: Health & Medicine.

Medical Buzz delivers the most recent headlines from the medical world. Diseases, cures, accidents, medicin. Click below for more headlines ...
Medical buzz